Neumora Therapeutics (NMRA) Gains from Sales and Divestitures (2023 - 2026)
Neumora Therapeutics' quarterly Gains from Sales and Divestitures came in at $13000.0 in Q1 2026, down 55.17% year-on-year from $29000.0 in Q1 2025, and down 81.16% quarter-over-quarter from $69000.0 in Q4 2025.
Neumora Therapeutics has reported Gains from Sales and Divestitures for 4 years, with the latest figure at $13000.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Sales and Divestitures fell 55.17% year-over-year to $13000.0; the trailing twelve-month figure through Mar 2026 stood at $13000.0 (down 55.17% YoY), and the FY2025 full-year result was $69000.0, down 21.59% from the prior year.
- Gains from Sales and Divestitures for Q1 2026 stood at $13000.0, down from $69000.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $2.5 million in Q4 2023, with the low at $13000.0 in Q1 2026.
- Average Gains from Sales and Divestitures over 4 years is $552000.0, with a median of $190000.0 recorded in 2024.
- Year-over-year, Gains from Sales and Divestitures tumbled 96.46% in 2024 and soared 320.45% in 2025.
- Tracing NMRA's Gains from Sales and Divestitures over 4 years: stood at $2.5 million in 2023, then plunged by 96.46% to $88000.0 in 2024, then retreated by 21.59% to $69000.0 in 2025, then slumped by 81.16% to $13000.0 in 2026.
- The last three Gains from Sales and Divestitures figures came in at $13000.0 (Q1 2026), $69000.0 (Q4 2025), and $370000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Neumora Therapeutics | 328.27 Mn | 328.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13,000.00 |
| Mar 31, 2026 | 13,000.00 |
| Dec 31, 2025 | 69,000.00 |
| Dec 31, 2025 | 69,000.00 |
| Sep 30, 2025 | 370,000.00 |
| Sep 30, 2025 | 370,000.00 |
| Jun 30, 2025 | 370,000.00 |
| Jun 30, 2025 | 370,000.00 |
| Mar 31, 2025 | 29,000.00 |
| Mar 31, 2025 | 29,000.00 |
| Dec 31, 2024 | 88,000.00 |
| Dec 31, 2024 | 88,000.00 |
| Sep 30, 2024 | 88,000.00 |
| Sep 30, 2024 | 88,000.00 |
| Jun 30, 2024 | 459,000.00 |
| Jun 30, 2024 | 459,000.00 |
| Mar 31, 2024 | 190,000.00 |
| Mar 31, 2024 | 190,000.00 |
| Dec 31, 2023 | 2.49 Mn |
| Dec 31, 2023 | 2.49 Mn |
| Sep 30, 2023 | 1.91 Mn |
| Sep 30, 2023 | 1.91 Mn |